Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00115089 | 7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis | PHASE2 | COMPLETED | 375 | — | — | Jul 1, 2005 | Sep 1, 2005 | Nov 11, 2005 | - | — |
| Name | Type | Description |
|---|---|---|
| R926112 | DRUG | - |
| Beclomethasone dipropionate | DRUG | - |
Inclusion Criteria: * Subjects must sign a written informed consent form and assent (if applicable) for study participation. * Males and females, 12 years of age or older * Subjects must have a history consistent with seasonal allergic rhinitis (SAR) during the fall pollen season for at least the p...